Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Has Average Target Price of $99.55

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation, nine have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $99.55.

HALO has been the subject of several analyst reports. TD Cowen upped their target price on Halozyme Therapeutics from $105.00 to $130.00 and gave the company a “buy” rating in a report on Tuesday, October 13th. Wall Street Zen upgraded Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 8th. Wells Fargo & Company upped their price objective on shares of Halozyme Therapeutics from $75.00 to $95.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research report on Tuesday, July 21st. Finally, Weiss Ratings upgraded shares of Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Monday, August 31st.

Halozyme Therapeutics Stock Down 0.2%

Halozyme Therapeutics stock opened at $130.91 on Friday. The company has a 50-day simple moving average of $113.70 and a 200-day simple moving average of $83.45. The firm has a market capitalization of $14.86 billion, a P/E ratio of 39.08, a P/E/G ratio of 0.49 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a quick ratio of 2.31 and a current ratio of 2.71. Halozyme Therapeutics has a one year low of $61.22 and a one year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating analysts’ consensus estimates of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million for the quarter, compared to analyst estimates of $402.28 million. During the same period last year, the company earned $1.54 earnings per share. The company’s quarterly revenue was up 47.7% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts expect that Halozyme Therapeutics will post 8.31 earnings per share for the current year.

Insider Activity

In other news, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40, for a total value of $2,188,000.00. Following the transaction, the chief executive officer directly owned 767,780 shares in the company, valued at approximately $83,995,132. The trade was a 2.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Matthew L. Posard sold 5,230 shares of the company’s stock in a transaction that occurred on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the transaction, the director owned 53,609 shares of the company’s stock, valued at approximately $5,818,720.86. This trade represents a 8.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock worth $13,538,046 in the last three months. 2.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently made changes to their positions in the business. Bank of America Corp DE bought a new stake in shares of Halozyme Therapeutics during the second quarter valued at approximately $214,504,000. William Blair Investment Management LLC bought a new position in Halozyme Therapeutics in the 2nd quarter worth approximately $196,540,000. Congress Asset Management Co. raised its position in Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after purchasing an additional 1,052,509 shares during the last quarter. Royal London Asset Management Ltd. lifted its holdings in Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock worth $141,732,000 after buying an additional 200,262 shares in the last quarter. Finally, First Trust Advisors LP lifted its holdings in Halozyme Therapeutics by 46.5% during the 1st quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock worth $95,804,000 after buying an additional 470,558 shares in the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.